Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ChronoScale Holdings Corp (CHRN)

ChronoScale director Scott Davis resigns from board after Ekso Bionics sale

Neutral Impact 3 of 5 leadership Written later

ChronoScale Holdings disclosed that director and Ekso Bionics CEO Scott Davis resigned from the board effective October 3, 2026, following the September 30, 2026 sale of Ekso Bionics. The company granted Davis 51,626 fully vested restricted stock units and agreed to a $709,500 release payment in exchange for a general release of claims, in place of severance he could otherwise have received.

Key points

  • Scott Davis resigned from the board effective October 3, 2026, with no disagreements cited
  • Davis received 51,626 fully vested RSUs granted October 2, 2026
  • Release Payment of $709,500, less withholdings, payable within 30 days of signing, subject to compliance with restrictive covenants
  • Release Agreement replaces payments under a November 5, 2025 Change in Control and Severance Agreement

The filing

CompanyChronoScale Holdings Corp (CHRN)
Form8-K, current report
Filed with the SECOct 6, 2026, 5:20 PM ET
Accession number0001493152-26-046010

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.